However, based on recent data [32], future prospective studies should investigate adjuvant chemotherapy or chemoradiotherapy for all patients with TP53 mutated tumors or p53 overexpression on IHC, independent of tumor stage and conventional risk stratification [16]. The gene discussed is TP53; the disease is neoplasm.